SPOTLIGHT: FDA contract draws scrutiny

The Los Angeles Times examines an FDA contract given to a company which was being advised by the husband of the FDA official who recommended it for the job. The official says the agency investigated it without finding any wrongdoing, but officials tell the LA Times they weren't aware of all the details. Article

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.